Moderna Stock Dives 5.46% Amid Profit-Taking After Rally

Moderna Inc (MRNA) stock fell by 5.46% on August 26 due to profit-taking following a multi-session rally.

The company's personalized mRNA cancer vaccine, intismeran autogene, developed in partnership with Merck, showed promising results in the Phase 3 INTerpath-001 trial for melanoma patients.

However, investors are cautious about the logistical complexities and significant capital expenditure required to manufacture individualized cancer vaccines at commercial scale.

The company's valuation friction also contributed to the pullback, with a sizable gap between current trading levels and consensus institutional price targets.